Table 2 CD20, RKIP and bcl-2 expression levels in specimen of cutaneous lymphoma relapse obtained at different time points since treatment start
From: Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma
CD20-positive cells (%) | RKIP-positive cells (%) | Bcl-2-positive cells (%) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patients | Timepoint of biopsy | <10 | 10–30 | 30–60 | 60–90 | >90 | <10 | 10–30 | 30–60 | 60–90 | >90 | <10 | 10–30 | 30–60 | 60–90 | >90 |
Patient 1 | At diagnosis | x | x | x | ||||||||||||
At relapse after 4 months (during therapy) | x | x | x | |||||||||||||
At relapse after 6 months (during therapy) | x | x | x | |||||||||||||
At relapse after 12 months (during therapy) | x | x | x | |||||||||||||
Patient 2 | At diagnosis | x | x | x | ||||||||||||
At relapse after 6 months (5 months since therapy cessation) | x | x | x | |||||||||||||
At relapse after 9 months (8 months since therapy cessation) | x | x | x | |||||||||||||
Patient 3 | At diagnosis | x | x | x | ||||||||||||
At relapse after 13 months (6 months since therapy cessation) | x | x | x | |||||||||||||
Patient 4 | At relapse after 4 months (2 months since therapy cessation) | x | x | x | ||||||||||||
At relapse after 30 months (28 months since therapy cessation) | x | x | x | |||||||||||||
